Abstract
Objectives
To assess the efficacy of cyclosporine (CsA) in patients of oral steroid unresponsive or steroid dependent systemic juvenile idiopathic arthritis (sJIA); to evaluate the optimum dosage and blood level of CsA to achieve and maintain remission and to observe for side-effects on prolonged usage.
Methods
This prospective observational study was conducted on children with steroid dependent /refractory sJIA admitted at the Institute of Child Health, Kolkata from July 2009 through November 2014. A total of 82 sJIA was diagnosed; 15 were steroid dependent /refractory and were included as candidates for cyclosporine therapy.
Results
CsA was used in 15 patients; 13 showed a favourable response with significant steroid sparing effect and minimal toxicity.
Conclusion
CsA was found to be effective in almost 75% of frequently relapsing steroid dependent sJIA to achieve and maintain remission. The average cost of therapy for a 20 kg patient on CsA was found to be 10,000 INR (132 EURO)/ patient over a 6 mo period; which would amount to 100,000 INR (1318 EURO)/patient with Tocilizumab for the same duration.
Similar content being viewed by others
References
Beukelmen T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–82.
Pay S, Turkcapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.
Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505–15.
Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071–5.
De Benedetti F, Brunner HI, Ruperto N, et al; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.
Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis: results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24:599–605.
Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis: results of a 10-year prospective study. Rheumatology (Oxford). 2001;40:907–13.
Ostensen M, Hoyerall HM, Kass E. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol. 1988;15:1536–8.
Wells G, Haguernauer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell P. Cyclosporine for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2:CD001083.
Gremese E, Ferraccioli GF. Benefit/risk of cyclosporine in rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:S101–7.
Ostensen M, Hoyeraal HM, Kass E. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol. 1988;15:1536–8.
Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol. 1993;11:203–8.
Ravelli A, Moretti C, Tomporini F, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:69–72.
Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333:137–41.
Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24:2436–43.
Author information
Authors and Affiliations
Contributions
PP conceptualised the project. Both PP and PPG were involved in patient management and data collection. All three authors drafted the manuscript. Prof. Apurba Ghosh, Director, Institute of Child Health, Kolkata will act as guarantor for this paper.
Corresponding author
Ethics declarations
Conflict of Interest
None
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pal, P., Giri, P.P. & Sinha, R. Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics. Indian J Pediatr 86, 590–594 (2019). https://doi.org/10.1007/s12098-019-02912-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-019-02912-9